News
Eli Lilly insiders made notable stock purchases in August, but competitive pressures and pricing risks make me question its ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...
While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...
Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.
The US drugmaker Eli Lilly has bowed to demands from Donald Trump by raising the prices of its weight-loss jab for UK ...
Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...
Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results